Pharmaceutical companies’ high pricing could threaten access to potential COVID-19 treatments, The Guardian reports.
Sofosbuvir, a hepatitis C drug, costs only about $5 to manufacture, but the list price in the U.S. is a staggering $18,610, according to the report.
“There has been a long history of big pharmaceutical companies charging unnecessary and unwarranted high prices for medications, even if they actually spent very little on research and development for that medication,” Jacob Levi, author of a study that looks at nine potential COVID-19 treatments, said.
To read the full report, click here.
